The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Antiphospholipid Antibodies and Subsequent Thrombo-occlusive Events in Patients With Ischemic Stroke
Open accessAbstract
CONTEXT: The presence of antiphospholipid antibodies (aPL) has been associated with vascular occlusive events. However, the role of aPL in predicting ischemic events, particularly recurrent ischemic stroke, is controversial. OBJECTIVE: To evaluate the effect of baseline aPL positivity (ie, positivity for anticardiolipin antibodies [aCL], lupus anticoagulant antibodies [LA], or both) on subsequent thrombo-occlusive events, including recurrent stroke. DESIGN, SETTING, AND PARTICIPANTS: The Antiphospholipid Antibodies and Stroke Study (APASS), a prospective cohort study within the Warfarin vs Aspirin Recurrent Stroke Study (WARSS), a randomized double-blind trial (N = 2206) conducted at multiple US clinical sites from June 1993 through June 2000 and comparing adjusted-dose warfarin (target international normalized ratio, 1.4-2.8) and aspirin (325 mg/d) for prevention of recurrent stroke or death. APASS participants were 1770 (80%) WARSS participants who consented to enroll in the APASS, with usable baseline blood samples drawn prior to randomization to the WARSS and analyzed for aPL status within 90 days of index stroke by a central independent laboratory. Quality assurance was performed on approximately 10% of samples by a second independent laboratory. MAIN OUTCOME MEASURE: Two-year rate of the composite end point of death from any cause, ischemic stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis, pulmonary embolism, and other systemic thrombo-occlusive events. The primary analysis assessed the outcome associated with aPL positivity within each WARSS treatment group separately, after risk-factor adjustment (since these aPL-positive vs aPL-negative comparisons were not randomized). RESULTS: Of the 1770 APASS patients, 720 (41%) were classified as aPL-positive and 1050 (59%) as aPL-negative. There was no increased risk of thrombo-occlusive events associated with baseline aPL status in patients treated with either warfarin (relative risk [RR], 0.99; 95% confidence interval [CI], 0.75-1.31; P =.94), or aspirin (RR, 0.94; 95% CI, 0.70-1.28; P =.71). The overall event rate was 22.2% among aPL-positive and 21.8% among aPL-negative patients. There was no treatment x aPL interaction (P =.91). Patients with baseline positivity for both LA and aCL antibodies tended to have a higher event rate (31.7%) than did patients who tested negative for both antibodies (24.0%) (unadjusted RR, 1.36; 95% CI, 0.97-1.92; P =.07). Classification and regression tree analyses did not identify a specific LA test or aCL isotype or titer that was associated with increased risk of thrombo-occlusive event. CONCLUSIONS: The presence of aPL (either LA or aCL) among patients with ischemic stroke does not predict either increased risk for subsequent vascular occlusive events over 2 years or a differential response to aspirin or warfarin therapy. Routine screening for aPL in patients with ischemic stroke does not appear warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As there is currently no evidence to support the superiority of oral anticoagulant therapy over antiplatelet therapy [15], antiplatelet drugs are generally recommended after an episode of stroke.”
From Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome (2010) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“An early study in older patients with strokes reported no difference in event recurrences between LDA and warfarin, but aPL was tested only once and was mainly of low titre in this study.33”
From EULAR recommendations for the management of antiphospholipid syndrome in adults (2019) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levine, J. S., Branch, D. W., & Rauch, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmra002974 · Cited by 1,524
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
Harris, E. N., Boey, M. L., Mackworth-Young, C. G., Gharavi, A. E., Patel, B. M., Loizou, S., & Hughes, G. R. V. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91267-9 · Cited by 1,383
A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke
Mohr, J. P., Thompson, J. L. P., Lazar, R. M., Levin, B., Sacco, R. L., Furie, K. L., Kistler, J. P., Albers, G. W., Pettigrew, L. C., Adams, H. P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011258 · Cited by 1,168
Brandt, J. T., Triplett, D. A., Alving, B. M., & Scharrer, I. (1995) · PubMed · Cited by 1,164
Brandt, J. T., Triplett, D. A., Alving, B., & Scharrer, I. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649901 · Cited by 993
Crowther, M. A., Ginsberg, J. S., Julian, J., Denburg, J., Hirsh, J., Douketis, J., Laskin, C., Fortin, P., Anderson, D., Kearon, C., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035241 · Cited by 919
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients
Rosove, M. H., & Brewer, P. M. C. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-4-303 · Cited by 700
Anticardiolipin Antibodies and the Risk for Ischemic Stroke and Venous Thrombosis
Ginsburg, K. S., Liang, M. H., Newcomer, L., Goldhaber, S. Z., Schur, P. H., Hennekens, C. H., & Stampfer, M. J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-12-997 · Cited by 526
Heart Valve Involvement (Libman-Sacks Endocarditis) in the Antiphospholipid Syndrome
Hojnik, M., George, J., Ziporen, L., & Shoenfeld, Y. (1996) · Circulation · doi:10.1161/01.cir.93.8.1579 · Cited by 443
Flagged first, then by citations
Research works printed but not linked: 5
- Rand JH, Wu X-X, Andree HAM, et al. Preg- nancy loss in the antiphospholipid-antibody syn- drome-a possible thrombogenic mechanism [pub- lished correction appears in N Engl J Med. 1997;337: 1327]. N Engl J Med. 1997;337:154-160.
- Levine JS, Branch DW, Rauch J. The antiphospho- lipid syndrome. N Engl J Med. 2002;346:752-763.
- WARSS, APASS, PICSS, and HAS Study Groups. The feasibility of a collaborative double-blind study using an anticoagulant: the Warfarin-Aspirin Recur- rent Stroke Study (WARSS), the Antiphospholipid An- tibodies And Stroke Study (APASS), the Patent fora- men ovale In Cryptogenic Stroke Study (PICSS), and the Hemostatic system Activation Study (HAS). Ce- rebrovasc Dis. 1997;7:100-112.
- WARSS Study Group. A double-blind study us- ing an anticoagulant: the design and initial progress of the Warfarin-Aspirin Recurrent Stroke Study (WARSS). Cerebrovasc Dis. 1997;7:100-112.
- Turhim S, Rand JH, Goldman M, et al. Antiphos- phatidylserine antibodies are independently associated with ischemic stroke. Neurology. 1999;53:1523-1527.
Cited by
Sorted by citations
Items 101–200 of 477
Clinical Impact of Thrombophilia Screening in Young Adults with Ischemic Stroke
Omran, S. S., Lerario, M. P., Gialdini, G., Merkler, A. E., Moya, A., Chen, M. L., Kamel, H., DeSancho, M. T., & Navi, B. B. (2018) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2018.12.006 · Cited by 44
Management of the neurological manifestations of APS—what do the trials tell us?
Brey, R. L. (2004) · Thrombosis Research · doi:10.1016/j.thromres.2004.06.018 · Cited by 44
Antiphospholipid (Hughes) Syndrome
Khamashta, M. A., Bertolaccini, M. L., & Hughes, G. R. V. (2004) · Autoimmunity · doi:10.1080/08916930410001708706 · Cited by 44
Antiphospholipid Syndrome in Pediatrics
Ravelli, A., & Martini, A. (2007) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2007.07.001 · Cited by 43
Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test?
Carroll, B., & Piazza, G. (2018) · Vascular Medicine · doi:10.1177/1358863x18755927 · Cited by 44
Pengo, V., Ruiz‐Irastorza, G., Denas, G., Andréoli, L., Khamashta, M. A., & Tincani, A. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.10.016 · Cited by 40
Antiphospholipid syndrome: a clinical review
Mezhov, V., Segan, J., Tran, H. A., & Cicuttini, F. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50262 · Cited by 41
Risk factors for ischemic stroke and transient ischemic attack in patients under age 50
Janssen, A. W. M., de Leeuw, F., & Janssen, M. C. H. (2010) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-010-0491-3 · Cited by 41
Ravelli, A., & Martini, A. (2005) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2005.01.001 · Cited by 40
Thrombophilia Testing After Ischemic Stroke
Omran, S. S., Hartman, A., Zakai, N. A., & Navi, B. B. (2021) · Stroke · doi:10.1161/strokeaha.120.032360 · Cited by 44
Antiphospholipid syndrome, antiphospholipid antibodies, and stroke
Mittal, P., Quattrocchi, G., Tohidi‐Esfahani, I., Sayar, Z., Chandratheva, A., & Cohen, H. (2022) · International Journal of Stroke · doi:10.1177/17474930221150349 · Cited by 41
Pediatric Antiphospholipid Syndrome
Aguiar, C. L., Soybilgic, A., Avčin, T., & Myones, B. L. (2015) · Current Rheumatology Reports · doi:10.1007/s11926-015-0504-5 · Cited by 39
New Treatments for Antiphospholipid Syndrome
Erkan, D., & Lockshin, M. D. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2005.09.004 · Cited by 39
Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome
Les, Í., Ruiz‐Irastorza, G., & Khamashta, M. A. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1304720 · Cited by 38
Peetz, D., von Landenberg, P., & Lackner, K. J. (2006) · Thrombosis and Haemostasis · doi:10.1160/th06-03-0132 · Cited by 38
Fuentes, B., Gállego, J., Gil-Núñez, A., Morales, A., Purroy, F. F., Roquer, J., Segura, T., Tejada, J., Lago, A. P., Díez‐Tejedor, E., et al. (2011) · Neurología · doi:10.1016/j.nrl.2011.06.003 · Cited by 39
Muscal, E., & Brey, R. L. (2008) · Current Rheumatology Reports · doi:10.1007/s11926-008-0012-y · Cited by 37
Berkman, S. A., & Song, S. S. (2021) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211002274 · Cited by 38
Platelets and Thrombotic Antiphospholipid Syndrome
Tohidi‐Esfahani, I., Mittal, P., Isenberg, D. A., Cohen, H., & Efthymiou, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030741 · Cited by 40
Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective
Pengo, V., & Denas, G. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.07.011 · Cited by 37
Prevalence of antiphospholipid antibodies in patients with neurological symptoms
Miesbach, W., Gilzinger, A., Gökpinar, B., Claus, D., & Scharrer, I. (2005) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2005.03.005 · Cited by 36
Management of Thrombotic Antiphospholipid Syndrome
Chighizola, C. B., Raimondo, M. G., & Meroni, P. L. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1597282 · Cited by 35
The Management of Stroke in Antiphospholipid Syndrome
Panichpisal, K., Rozner, E., & Levine, S. R. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-011-0223-5 · Cited by 36
Antiphospholipid Antibodies and Risk for Recurrent Vascular Events—Reply
Levine, S. R., Brey, R. L., Tilley, B. C., Triplett, D. A., Thompson, J. L. P., Sacco, R. L., Mohr, J. P., & for the APASS Investigators, F. T. A. I. (2004) · JAMA · doi:10.1001/jama.291.22.2702 · Cited by 35
Neurologic manifestations of the antiphospholipid syndrome
Roldán, J. F., & Brey, R. L. (2007) · Current Rheumatology Reports · doi:10.1007/s11926-007-0004-3 · Cited by 36
Neuropsychiatric Manifestations of Antiphospholipid Syndrome—A Narrative Review
Man, Y. L., & Sanna, G. (2022) · Brain Sciences · doi:10.3390/brainsci12010091 · Cited by 34
Rajamani, K., Chaturvedi, S., Jin, Z., Homma, S., Brey, R. L., Tilley, B. C., Sacco, R. L., Thompson, J. L. P., Mohr, J. P., & Levine, S. R. (2009) · Stroke · doi:10.1161/strokeaha.108.539171 · Cited by 34
Pastori, D., Bucci, T., Triggiani, M., Ames, P. R. J., Parrotto, S., Violi, F., Pignatelli, P., & Farcomeni, A. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.03.005 · Cited by 33
Evidence based treatment of the antiphospholipid syndrome
Crowther, M. A., & Wislöff, F. (2004) · Thrombosis Research · doi:10.1016/j.thromres.2004.06.041 · Cited by 34
Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio
Amory, C. F., Levine, S. R., Brey, R. L., Gebregziabher, M., Tuhrim, S., Tilley, B. C., Simpson, A.-C. C., Sacco, R. L., Mohr, J. P., & Collaborators, F. T. A.-W. (2015) · Cerebrovascular Diseases · doi:10.1159/000441362 · Cited by 31
Garcia, D. A., Khamashta, M. A., & Crowther, M. A. (2007) · Blood · doi:10.1182/blood-2006-10-041814 · Cited by 33
Antiphospholipid antibiodies: a critical review of the literature
Lim, W., & Crowther, M. A. (2007) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3282a4a65f · Cited by 32
Treatment of antiphospholipid syndrome
Radin, M., Cecchi, I., Rubini, E., Foddai, S. G., Barinotti, A., Menegatti, E., Roccatello, D., & Sciascia, S. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108597 · Cited by 32
Management of Antiphospholipid Syndrome
Ghembaza, A., & Saadoun, D. (2020) · Biomedicines · doi:10.3390/biomedicines8110508 · Cited by 50
Cheng, C., Cheng, G.-Y., Denas, G., & Pengo, V. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100788 · Cited by 36
Diagnosis and treatment of antiphospholipid syndrome in childhood: A review
Rumsey, D. G., Myones, B. L., & Massicotte, P. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.02.009 · Cited by 30
Kassis, J., Solymoss, S., Joseph, L., Bélisle, P., Levine, J. S., Neville, C., Rauch, J., & Fortin, P. R. (2008) · Thrombosis and Haemostasis · doi:10.1160/th08-06-0384 · Cited by 31
Linnemann, B., Schindewolf, M., Zgouras, D., Erbe, M., Jarosch-Preusche, M., & Lindhoff‐Last, E. (2007) · Thrombosis Research · doi:10.1016/j.thromres.2007.07.014 · Cited by 31
D’Cruz, D. P., & Khamashta, M. A. (2009) · Springer eBooks · doi:10.1007/978-1-84800-934-9_16 · Cited by 31
Towards evidence-based treatment of thrombotic antiphospholipid syndrome
Derksen, R. H. W. M., & de Groot, P. G. (2010) · Lupus · doi:10.1177/0961203309361483 · Cited by 30
Patent foramen ovale and prothrombotic markers in young stroke patients
Belvís, R., Santamaría, A., Martí‐Fábregas, J., Leta, R., Cocho, D., Borrell, M., Fontcuberta, J., & Jl, M.-V. (2007) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e3281420398 · Cited by 29
Cognitive dysfunction and white matter abnormalities in antiphospholipid syndrome
Erkan, D., Kozora, E., & Lockshin, M. D. (2010) · Pathophysiology · doi:10.1016/j.pathophys.2010.04.010 · Cited by 30
Stroke and antiphospholipid syndrome: the treatment debate
Ruiz‐Irastorza, G., & Khamashta, M. A. (2005) · Rheumatology · doi:10.1093/rheumatology/keh666 · Cited by 30
Bazzan, M., Vaccarino, A., Stella, S., Bertero, M., CARIGNOLA, R., Montaruli, B., Roccatello, D., & Shoenfeld, Y. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.11.007 · Cited by 28
Armstrong, E. M., Bellone, J. M., Hornsby, L. B., Eudaley, S. T., & Phillippe, H. M. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014530424 · Cited by 31
Immunologically mediated dementias
Rosenbloom, M. H., Smith, S. W., Akdal, G., & Geschwind, M. D. (2009) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-009-0053-2 · Cited by 28
Pasquali, J., Poindron, V., Korganow, A., & Martin, T. (2008) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2008.08.008 · Cited by 28
Recognition and management of antiphospholipid syndrome
Gerosa, M., Meroni, P. L., & Erkan, D. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000240 · Cited by 26
Cáliz, R., Fontecha, P. D. D. C., Galindo-Izquierdo, M., Longo, F. J. L., Zamora, M. Á. M., Santamaría, A., Pliego, O. A., Lozano, M. J. C., Beltrán, M. P. D., Carmona, L., et al. (2019) · Reumatología Clínica · doi:10.1016/j.reuma.2018.11.003 · Cited by 26
Muscal, E., & Brey, R. L. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01478.x · Cited by 25
Treatment of Risk Factors to Prevent Stroke
Aoki, J., & Uchino, K. (2011) · Neurotherapeutics · doi:10.1007/s13311-011-0054-0 · Cited by 25
Anti-Phosphatidylserine-Prothrombin Antibodies are Associated with Outcome in a TIA Cohort
Mullen, M. T., Messe, S. R., Kasner, S. E., Sansing, L. H., Husain, M. R., Norman, G. L., Shums, Z., & Cucchiara, B. L. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00137 · Cited by 26
Erkan, D., & Lockshin, M. D. (2006) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000218943.89365.13 · Cited by 26
Silva, G. S., Koroshetz, W. J., González, R., & Schwamm, L. H. (2010) · Springer eBooks · doi:10.1007/978-3-642-12751-9_2 · Cited by 26
Antiphospholipid Syndrome: Review
Sammaritano, L. R. (2005) · Southern Medical Journal · doi:10.1097/01.smj.0000166748.90089.65 · Cited by 26
The chequered history of the antiphospholipid syndrome
Arachchillage, D. J., & Greaves, M. (2014) · British Journal of Haematology · doi:10.1111/bjh.12848 · Cited by 25
Hughes syndrome (the antiphospholipid syndrome): 25 years old
Edwards, C. J., & Hughes, G. R. V. (2008) · Modern Rheumatology · doi:10.1007/s10165-008-0042-3 · Cited by 25
What is the appropriate anticoagulation strategy for thrombotic antiphospholipid syndrome?
Arachchillage, D. J., & Laffan, M. (2020) · British Journal of Haematology · doi:10.1111/bjh.16431 · Cited by 26
Long-Term Therapy to Prevent Stroke
Kirshner, H. S., Biller, J., & Callahan, A. (2005) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.18.6.528 · Cited by 23
Evaluation and Management of Stroke in Young Adults
Mackey, J. S. (2014) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000446106.74796.e9 · Cited by 23
Fuentes, B., Gállego, J., Gil-Núñez, A., Morales, A., Purroy, F. F., Roquer, J., Segura, T., Tejada, J., Lago, A. P., Díez‐Tejedor, E., et al. (2014) · Neurología (English Edition) · doi:10.1016/j.nrleng.2011.06.006 · Cited by 23
Role of Investigating Thrombophilic Disorders in Young Stroke
Ng, K. W. P., Loh, P. K., & Sharma, V. K. (2011) · Stroke Research and Treatment · doi:10.4061/2011/670138 · Cited by 22
A Review of Hereditary and Acquired Coagulation Disorders in the Aetiology of Ischaemic Stroke
de Lau, L. M. L., Leebeek, F. W. G., de Maat, M. P. M., Koudstaal, P. J., & Dippel, D. W. J. (2010) · International Journal of Stroke · doi:10.1111/j.1747-4949.2010.00468.x · Cited by 24
The treatment of antiphospholipid syndrome: A harmonic contrast
Ruiz‐Irastorza, G., & Khamashta, M. A. (2007) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2007.10.003 · Cited by 23
Prevention of Stroke in Rheumatoid Arthritis
Zha, A. M., Napoli, M. D., & Behrouz, R. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0600-y · Cited by 22
Dragoni, F., Chiarotti, F., Rosano, G. M. C., Simioni, P., Tormene, D., Mazzucconi, M. G., Cafolla, A., & Avvisati, G. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.11.013 · Cited by 22
Green, D. J., Maloney, D. G., Storer, B. E., Sandmaier, B. M., Holmberg, L. A., Becker, P. S., Fang, M., Martin, P. J., Georges, G. E., Bouvier, M. E., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010686 · Cited by 23
Ortel, T. L. (2006) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-006-5581-x · Cited by 22
Controversies in the antiphospholipid syndrome: can we ever stop warfarin?
Fonseca, A. G., & D’Cruz, D. P. (2008) · Journal of Autoimmune Diseases · doi:10.1186/1740-2557-5-6 · Cited by 23
Urbanski, G., Yelnik, C., Maillard, H., Launay, D., Dubucquoi, S., HACHULLA, E., Hatron, P., & Lambert, M. (2018) · Stroke · doi:10.1161/strokeaha.118.023021 · Cited by 22
Gonthier, A., & Bogousslavsky, J. (2004) · Revue Neurologique · doi:10.1016/s0035-3787(04)71140-6 · Cited by 22
Hamann, G. F., Sander, D., Grau, A., & Röther, J. (2022) · DGNeurologie · doi:10.1007/s42451-022-00461-8 · Cited by 21
Fujimoto, M., Asano, Y., Ishii, T., Ogawa, F., Kawakami, T., Kodera, M., Abe, M., Isei, T., Ito, T., Inoue, Y., et al. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13275 · Cited by 21
Hughes syndrome and epilepsy: when to test for antiphospholipid antibodies?
Noureldine, M. H. A., Harifi, G., Berjawi, A., Haydar, A. A., Nader, M., Nawar, R. E., Sweid, A., Saleh, J. A., Khamashta, M. A., & Uthman, I. W. (2016) · Lupus · doi:10.1177/0961203316651747 · Cited by 23
Martinelli, I., Passamonti, S. M., & Bucciarelli, P. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-7020-4087-0.00071-1 · Cited by 21
Management of Antiphospholipid Antibody Syndrome
Lim, W., & Crowther, M. A. (2008) · Wiley eBooks · doi:10.1002/9781444300857.ch21 · Cited by 21
Inflammatory Manifestations of Systemic Diseases in the Central Nervous System
Lapides, D. A., & McDonald, M. M. (2020) · Current Treatment Options in Neurology · doi:10.1007/s11940-020-00636-2 · Cited by 21
Antiphospholipid Antibody and Recurrent Ischemic Stroke
Kim, Y., & Kim, S. Y. (2020) · Stroke · doi:10.1161/strokeaha.120.030431 · Cited by 20
Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-Analysis
Aibar, J., & Schulman, S. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1725057 · Cited by 22
Treatment of the antiphospholipid syndrome
Galli, M. (2013) · Autoimmunity Highlights · doi:10.1007/s13317-013-0056-5 · Cited by 38
Cryptogenic Stroke: How to Define It? How to Treat It?
Liberman, A. L., & Prabhakaran, S. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0423-x · Cited by 20
Diretrizes para o tratamento da síndrome do anticorpo antifosfolipídeo
Danowski, A., Rêgo, J., Kakehasi, A. M., Funke, A., de Carvalho, J. F., Lima, I., de Souza, A. W. S., & Levy, R. A. (2013) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042013000200005 · Cited by 21
Guidelines for the treatment of antiphospholipid syndrome
Danowski, A., Rêgo, J., Kakehasi, A. M., Funke, A., de Carvalho, J. F., Lima, I., de Souza, A. W. S., & Levy, R. A. (2013) · Revista Brasileira de Reumatologia (English Edition) · doi:10.1016/s2255-5021(13)70021-x · Cited by 19
Maes, M. H. J., Nikiforov, N. G., Plaimas, K., Suratanee, A., Alfieri, D. F., & Reiche, E. M. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212108 · Cited by 19
Evolution of Antiphospholipid Syndrome
Arachchillage, D. J., & Pericleous, C. (2023) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1760333 · Cited by 21
Clinically Translated Ischemic Stroke Genomics
Meschia, J. F. (2004) · Stroke · doi:10.1161/01.str.0000143156.32467.fd · Cited by 18
Controversies and Unresolved Issues in Antiphospholipid Syndrome Pathogenesis and Management
Baker, W., Bick, R. L., & Fareed, J. (2008) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.10.006 · Cited by 18
Antiphospholipid syndrome presenting as cerebral venous sinus thrombosis: a case series and a review
Shlebak, A. A. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-203077 · Cited by 19
Secondary Prevention of Stroke
Koennecke, H. (2004) · CNS Drugs · doi:10.2165/00023210-200418040-00003 · Cited by 18
Katramados, A. M., Rabah, R. M., Adams, M., Huq, A. M., & Mitsias, P. (2008) · Lupus · doi:10.1177/0961203307086638 · Cited by 18
The Challenge of Stroke Prevention
Hanley, D. F. (2004) · JAMA · doi:10.1001/jama.291.5.621 · Cited by 18
Role of anticardiolipin antibodies in the pathogenesis of prosthetic valve thrombosis
Aykan, A. Ç., Gökdeniz, T., Kalçık, M., Astarcıoğlu, M. A., Gündüz, S., Karakoyun, S., Gürsoy, M. O., Oğuz, A. E., Ertürk, E., Çakal, B., et al. (2014) · Herz · doi:10.1007/s00059-013-4038-1 · Cited by 17
Sex Differences in Antiplatelet Response in Ischemic Stroke
Meyer, D. M., Eastwood, J., Compton, M. P., Gylys, K. H., Zivin, J. A., & Ovbiagele, B. I. (2011) · Women s Health · doi:10.2217/whe.11.45 · Cited by 17
Relation of Antiphospholipid Antibodies to Postmortem Brain Infarcts in Older People
Arvanitakis, Z., Brey, R. L., Rand, J. H., Schneider, J. A., Capuano, A. W., Yu, L., Leurgans, S. E., Bennett, D. A., & Levine, S. R. (2014) · Circulation · doi:10.1161/circulationaha.114.012479 · Cited by 17
Prognosis after Cryptogenic Cerebral Ischemia in Patients with Coagulopathies
Weber, R., Goertler, M., Benemann, J., Diener, H., & Weimar, C. (2009) · Cerebrovascular Diseases · doi:10.1159/000251172 · Cited by 17
Antiphospholipid syndrome in patients with retinal venous occlusion
Paccalin, M., Manic, H., Bouche, G., Landron, C., Mercié, M., Boinot, C., Gombert, J., Roblot, P., & Dighiero, P. (2005) · Thrombosis Research · doi:10.1016/j.thromres.2005.03.005 · Cited by 17
Direct Oral Anticoagulants for Thromboprophylaxis in Patients with Antiphospholipid Syndrome
Efthymiou, M., Gates, C., Isenberg, D. A., & Cohen, H. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1597902 · Cited by 16
Antiphosphatidylserine Antibodies and Clinical Outcomes in Patients With Acute Ischemic Stroke
Bu, X., Peng, H. Y., Zhong, C., Xu, T., Xu, T., Peng, Y., Chen, C.-S., Wang, J., Ju, Z., Li, Q., et al. (2016) · Stroke · doi:10.1161/strokeaha.116.013827 · Cited by 16
Rodríguez-Sanz, A., Martínez‐Sánchez, P., Prefasi, D., Fuentes, B., Pascual‐Salcedo, D., Blanco-Bañares, M. J., & Díez‐Tejedor, E. (2014) · Autoimmunity · doi:10.3109/08916934.2014.988329 · Cited by 16
The Course of Anticardiolipin Antibody Levels Under Immunoadsorption Therapy
Hauser, A.-C., Hauser, L., Pabinger-Fasching, I., Quehenberger, P., Derfler, K., & Hörl, W. H. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.05.023 · Cited by 16
Metadata
- Authors
- APASS Investigators
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- APASS Investigators
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2004-02-04
- Volume
- 291
- Issue
- 5
- Pages
- 576
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2110502968
- Cited by
- 478
- References
- 41
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 10 · 2023: 7 · 2022: 8 · 2021: 15 · 2020: 17 · 2019: 21 · 2018: 11 · 2017: 20 · 2016: 19 · 2015: 21 · 2014: 23 · 2013: 15 · 2012: 27
- FWCI
- 23.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (1K24NS43992, K24NS043992, 1R01 NS 30896, R01NS030896, 1R01 NS 28371, R01NS028371)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- antiphospholipid antibodies, anticardiolipin antibodies, lupus anticoagulant, recurrent ischemic stroke, warfarin, aspirin, stroke prevention, transient ischemic attack, myocardial infarction, deep vein thrombosis, pulmonary embolism, risk prediction
- MeSH terms
- Aged, Anticoagulants, Aspirin, Female, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Prospective Studies, Thrombosis, Warfarin, Cohort Studies, Proportional Hazards Models, Survival Analysis, Randomized Controlled Trials as Topic, Antibodies, Antiphospholipid, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
